Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2022-05-03 Major Shareholding Noti…
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
TOTAL VOTING RIGHTS
Major Shareholding Notification Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content focuses on the total voting rights as of April 30, 2022, including the number of issued shares and voting rights. It references the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1 and provides information relevant to shareholders for notification purposes. The document is relatively short (3152 characters) and primarily serves as a notification of voting rights rather than a detailed report or financial statement. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes or status of significant share ownership or voting rights. It is not an announcement of voting results (DVA) nor a full annual or interim report. Therefore, the best classification is MRQ with high confidence.
2022-05-03 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a notification filed under the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. It explicitly states the total number of voting rights (1,549,464,013) as of a specific date (30 April 2022). This type of filing, which relates to the total voting rights and capital structure for transparency purposes, aligns most closely with the definition of a general regulatory announcement or a specific filing related to share capital/voting rights. Since there is no specific code for 'Voting Rights Notification' outside of DVA (Declaration of Voting Results), and this is a routine regulatory disclosure about the total number of shares with voting rights, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a standard disclosure mandated by the exchange/regulator, rather than a specific event like a dividend (DIV) or a major shareholding change (MRQ). The presence of 'RNS Number' and the closing statement confirming RNS as the Primary Information Provider strongly supports the RNS classification.
2022-05-03 English
RESULT OF AGM
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, reporting the results of the Annual General Meeting (AGM) held on 29 April 2022. It contains detailed voting results for each resolution proposed at the AGM, including ordinary and special resolutions. The content focuses exclusively on the outcome of the shareholder votes at the AGM, with no financial statements or management discussion included. The document is about the official announcement of voting results from the AGM, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (7145 characters) and detailed vote tabulation further support this classification rather than a brief announcement or a full AGM presentation.
2022-04-29 English
Result of AGM
AGM Information Classification · 100% confidence The document explicitly states 'Results of Annual General Meeting held on 29 April 2022' and details the voting outcomes for various resolutions (e.g., receiving accounts, reappointing directors, approving remuneration). This content directly corresponds to the reporting of outcomes from an Annual General Meeting (AGM). The filing type code AGM-R (AGM Information) is the most appropriate classification, as it covers presentations and materials shared during the AGM, which includes the results announcement.
2022-04-29 English
Special Business Approved at AGM
AGM Information Classification · 99% confidence The document explicitly details 'RESOLUTIONS OF ASTRAZENECA PLC' passed at an 'Annual General Meeting' held on 'Friday 29 April 2022'. The content consists entirely of the specific resolutions voted upon, covering authorization to allot shares (Resolutions 8, 9, 10), authority for market purchases of shares (Resolution 11), and approval of a share option scheme (Resolution 13). This content is characteristic of the formal documentation resulting from an AGM, specifically the results of the votes taken. While it relates to capital changes (SHA/CAP), the primary context is the formal record of the meeting's outcomes. The most fitting category is 'AGM Information' (AGM-R), which covers presentations and materials shared during the AGM. Since this is the formal record of the resolutions passed, it is the core material of the AGM.
2022-04-29 English
ASTRAZENECA PLANS NEW R&D CENTRE IN MASSACHUSETTS
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It announces plans for a new R&D centre and corporate headquarters in Massachusetts. The content is an announcement of a corporate development and does not contain financial statements, earnings data, or detailed management discussion. It is not an annual or interim report, nor a call transcript or audit report. The document is a regulatory announcement about a strategic business development. Form 6-K filings typically fall under Regulatory Filings (RNS) as they are periodic reports of material information by foreign issuers that do not fit other specific categories. The document length is 4816 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-04-29 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.